This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsTurnstone Biologics (TSBX) 주식 개요턴스톤 바이오로직스는 생명공학 회사로 운영되고 있습니다. 자세히 보기TSBX 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성4/6배당0/6위험 분석수익이 USD$1m 미만입니다($0)cash runway 경력이 1년 미만입니다.의미 있는 시가총액이 없습니다($8M)지난 5년간 매년 수익이 34.7% 감소했습니다.모든 위험 점검 보기TSBX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.35해당 없음내재 할인율Est. Revenue$PastFuture-75m87m2016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesTurnstone Biologics Corp. 경쟁사bioAffinity TechnologiesSymbol: NasdaqCM:BIAFMarket cap: US$7.6mIN8bioSymbol: NasdaqCM:INABMarket cap: US$14.3mGalmed PharmaceuticalsSymbol: NasdaqCM:GLMDMarket cap: US$3.8mTAO SynergiesSymbol: NasdaqCM:TAOXMarket cap: US$33.9m가격 이력 및 성과Turnstone Biologics 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.3552주 최고가US$2.3352주 최저가US$0.29베타1.371개월 변동-3.56%3개월 변동1.46%1년 변동-84.22%3년 변동n/a5년 변동n/aIPO 이후 변동-96.77%최근 뉴스 및 업데이트공시 • Aug 12Turnstone Biologics Corp.(NasdaqCM:TSBX) dropped from NASDAQ Composite IndexTurnstone Biologics Corp has been dropped from the NASDAQ Composite Index.공시 • Aug 11XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Turnstone Biologics Corp. (NasdaqCM:TSBX).XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. (NasdaqCM:TSBX) on June 27, 2025. Turnstone will be required to pay XOMA a termination fee of $350,000. If XOMA terminates the Merger Agreement due to the failure of the Closing Net Cash Condition, the Company will be required to pay to XOMA an expense reimbursement fee up to a maximum amount of $350,000. Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the transaction. The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions. Pursuant and subject to the terms of the MergerAgreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remainingshares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Leerink Partners is acting as financial advisor and Divakar Gupta and Rama Padmanabhan of Cooley LLP is acting as legal counsel to Turnstone. Ryan A. Murr and Branden C. Berns of Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty. XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Turnstone Biologics Corp. (NasdaqCM:TSBX) on August 11, 2025. As of the Expiration Date, a total of 17,192,002 shares of Turnstone common stock were validly tendered, and not validly withdrawn, representing approximately 74% of the outstanding shares of Turnstone common stock as of the Expiration Date.공시 • Jun 27XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp.XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. (NasdaqCM:TSBX) on June 27, 2025. Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the transaction. The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions. Pursuant and subject to the terms of the MergerAgreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remainingshares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Leerink Partners is acting as financial advisor and Cooley LLP is acting as legal counsel to Turnstone. Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty.공시 • Apr 02Nasdaq Approves to Transfer Listing of Turnstone Biologics Common Stock from Nasdaq Global to Nasdaq Capital MarketAs previously reported, on September 27, 2024, Turnstone Biologics Corp. received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer met the minimum bid price requirement set in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) because the closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company had a 180-calendar day grace period, or until March 26, 2025, to regain compliance with the Minimum Bid Price Requirement. On March 24, 2025, the Company applied to transfer the listing of its common stock from The Nasdaq Global Market to The Nasdaq Capital Market. On March 27, 2025, the Company received approval from the Listing Qualifications Department of Nasdaq to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). The Company’s securities will be transferred to the Capital Market at the opening of business on March 31, 2025. The Company’s common stock will continue to trade under the symbol “TSBX.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. In connection with the Approval, the Company has been granted an additional 180-day grace period, or until September 22, 2025, to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day grace period. If the Company does not regain compliance during this additional grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that in order to regain compliance with the Minimum Bid Price Requirement during the additional grace period, it will implement a reverse stock split, and has filed a proxy statement soliciting a stockholder vote on such reverse stock split. If the Company’s stock becomes subject to delisting as a result of the Company’s failure to regain compliance with the Minimum Bid Price Requirement by September 22, 2025, the Company may appeal the decision to a Nasdaq Hearings Panel. In the event of an appeal, the Company’s common stock would remain listed on the Nasdaq Capital Market pending a written decision by the Nasdaq Hearings Panel following a hearing. In the event that the Nasdaq Hearings Panel determines not to continue the Company’s listing and the Company’s common stock is delisted from The Nasdaq Capital Market, the Company’s common stock may trade on the OTC Bulletin Board or other small trading markets, such as the pink sheets.Price Target Changed • Apr 01Price target decreased by 58% to US$1.00Down from US$2.38, the current price target is provided by 1 analyst. New target price is 166% above last closing price of US$0.38. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$16.10 next year compared to a net loss per share of US$3.07 last year.Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Will Waddill was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.더 많은 업데이트 보기Recent updates공시 • Aug 12Turnstone Biologics Corp.(NasdaqCM:TSBX) dropped from NASDAQ Composite IndexTurnstone Biologics Corp has been dropped from the NASDAQ Composite Index.공시 • Aug 11XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Turnstone Biologics Corp. (NasdaqCM:TSBX).XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. (NasdaqCM:TSBX) on June 27, 2025. Turnstone will be required to pay XOMA a termination fee of $350,000. If XOMA terminates the Merger Agreement due to the failure of the Closing Net Cash Condition, the Company will be required to pay to XOMA an expense reimbursement fee up to a maximum amount of $350,000. Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the transaction. The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions. Pursuant and subject to the terms of the MergerAgreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remainingshares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Leerink Partners is acting as financial advisor and Divakar Gupta and Rama Padmanabhan of Cooley LLP is acting as legal counsel to Turnstone. Ryan A. Murr and Branden C. Berns of Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty. XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Turnstone Biologics Corp. (NasdaqCM:TSBX) on August 11, 2025. As of the Expiration Date, a total of 17,192,002 shares of Turnstone common stock were validly tendered, and not validly withdrawn, representing approximately 74% of the outstanding shares of Turnstone common stock as of the Expiration Date.공시 • Jun 27XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp.XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. (NasdaqCM:TSBX) on June 27, 2025. Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the transaction. The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions. Pursuant and subject to the terms of the MergerAgreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remainingshares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Leerink Partners is acting as financial advisor and Cooley LLP is acting as legal counsel to Turnstone. Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty.공시 • Apr 02Nasdaq Approves to Transfer Listing of Turnstone Biologics Common Stock from Nasdaq Global to Nasdaq Capital MarketAs previously reported, on September 27, 2024, Turnstone Biologics Corp. received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer met the minimum bid price requirement set in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) because the closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company had a 180-calendar day grace period, or until March 26, 2025, to regain compliance with the Minimum Bid Price Requirement. On March 24, 2025, the Company applied to transfer the listing of its common stock from The Nasdaq Global Market to The Nasdaq Capital Market. On March 27, 2025, the Company received approval from the Listing Qualifications Department of Nasdaq to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). The Company’s securities will be transferred to the Capital Market at the opening of business on March 31, 2025. The Company’s common stock will continue to trade under the symbol “TSBX.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. In connection with the Approval, the Company has been granted an additional 180-day grace period, or until September 22, 2025, to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day grace period. If the Company does not regain compliance during this additional grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that in order to regain compliance with the Minimum Bid Price Requirement during the additional grace period, it will implement a reverse stock split, and has filed a proxy statement soliciting a stockholder vote on such reverse stock split. If the Company’s stock becomes subject to delisting as a result of the Company’s failure to regain compliance with the Minimum Bid Price Requirement by September 22, 2025, the Company may appeal the decision to a Nasdaq Hearings Panel. In the event of an appeal, the Company’s common stock would remain listed on the Nasdaq Capital Market pending a written decision by the Nasdaq Hearings Panel following a hearing. In the event that the Nasdaq Hearings Panel determines not to continue the Company’s listing and the Company’s common stock is delisted from The Nasdaq Capital Market, the Company’s common stock may trade on the OTC Bulletin Board or other small trading markets, such as the pink sheets.Price Target Changed • Apr 01Price target decreased by 58% to US$1.00Down from US$2.38, the current price target is provided by 1 analyst. New target price is 166% above last closing price of US$0.38. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$16.10 next year compared to a net loss per share of US$3.07 last year.Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Will Waddill was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 05Turnstone Biologics Corp. Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer Annual MeetingTurnstone Biologics Corp. announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. In collaboration with the University of Montreal Hospital Research Centre (CRCHUM). Although tumor-reactive TIL infused to patients are associated with clinical responses, there are currently no biomarkers that can predict whether tumor-reactive T cells can be expanded from a tumor. Using single T cell sequencing, this poster illustrates a manufacturing method tested to enrich TIL in tumor-reactive T cells, the results for which suggest that the degree of baseline TCR (T cell repertoire) overlap between blood and tumor repertoire could help identify patients from which tumor-reactive TIL can be expanded.공시 • Oct 11+ 1 more updateTurnstone Biologics Corp. Announces CFO ChangesTurnstone Biologics Corp. announced a strategic prioritization of its pipeline, as well as a workforce reduction of approximately 60% and changes to its leadership team, to focus resources on the continued advancement of its Phase 1 program, TIDAL-01. As a result of the restructuring initiatives that align with the Company’s near-term goals, the anticipated cost savings are expected to extend its cash runway into the second quarter of 2026 and maximize shareholder value. Wendy Worcester, CPA, current Vice President of Finance, will assume responsibility of the Finance function as the Principal Financial and Accounting Officer. Ms. Worcester joined Turnstone in 2022 and is a skilled business and finance professional with over 20 years of financial and accounting experience. Venkat Ramanan, Ph.D., will be stepping down from his role as Chief Financial Officer.공시 • Oct 02Turnstone Biologics Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market under Listing Rule 5450(a)(1)On September 27, 2024, Turnstone Biologics Corp. received notice (the ‘Notice’) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (‘Nasdaq’) that, because the closing bid price of Turnstone’s common stock was below $1.00 per share for 30 consecutive business days, Turnstone no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of Turnstone’s common stock on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until March 26, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to March 26, 2025. If Turnstone does not regain compliance by March 26, 2025, the Company may be eligible for an additional 180 calendar day grace period if it applies to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. To qualify, Turnstone would be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards, with the exception of the minimum bid price requirement, and provide written notice to Nasdaq of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff determines that Turnstone will not be able to cure the deficiency, or if Turnstone is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that Turnstone’s common stock will be subject to delisting. Turnstone is presently evaluating potential actions to regain compliance with the continued listing requirements of Nasdaq. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.공시 • Aug 15Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal CancerTurnstone Biologics Corp. reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer (“MSS mCRC”). Turnstone’s Phase 1 STARLING trial is an ongoing muti-site, first-in-human, non-randomized, open label, single-dose study, and is evaluating the safety, tolerability, and clinical activity of TIDAL-01. The trial is currently enrolling patients with colorectal cancer, head and neck squamous cell carcinoma, and uveal melanoma. As of the cutoff date of July 15, 2024, key takeaways from the initial data include the following: Clinical Responses: Among the four evaluable MSS mCRC patients included in the study, Turnstone observed a 25% overall response rate ("ORR") and 50% disease control rate ("DCR"). One patient demonstrated a deep and durable ongoing complete response (CR). Durability of Response: 50% of patients showed sustained clinical benefit, with notable progression free survival of over one year in the patient with ongoing complete response and 6 months for a patient with stable disease. Translational Profile: The TIDAL-01 process demonstrated the ability to generate high titer, polyclonal and multi-epitope tumor neoantigen-reactive T cells that expanded in the patient, persisted in the blood and correlated with an increase in CD8 T cell tumor infiltration. Tolerability Profile: TIDAL-01 was generally well-tolerated and safety events observed were consistent with known AEs associated with the lymphodepletion regimen, and IL-2 and pembrolizumab administration. Manufacturing Rates: The manufacturing success rate for TIDAL-01 in CRC for patients with sufficient starting material was 80%, which is consistent with other early clinical-stage cell therapy processes. The target dose of at least 1x10 total T cells was exceeded in all manufactured CRC products.공시 • Jul 03Turnstone Biologics Corp.(NasdaqGM:TSBX) dropped from Russell 3000 IndexTurnstone Biologics Corp.(NasdaqGM:TSBX) dropped from Russell 3000 Index분석 기사 • May 08We're A Little Worried About Turnstone Biologics' (NASDAQ:TSBX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...공시 • Apr 24Turnstone Biologics Corp., Annual General Meeting, Jun 03, 2024Turnstone Biologics Corp., Annual General Meeting, Jun 03, 2024, at 13:30 Pacific Standard Time. Agenda: To elect the three nominees for Class I directors named in the accompanying proxy statement (the “Proxy Statement”) to hold office until the 2027 Annual Meeting of Stockholders and his or her successor has been duly elected and qualified or, if sooner, until such director’s earlier death, resignation or removal; to ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting.공시 • Apr 17Turnstone Biologics Corp. Announces Board ChangesTurnstone Biologics Corp. announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. Mr. Waddill brings more than three decades of financial and operational expertise in the biotechnology space, and proven leadership in industry organizations. Mr. Waddill currently sits on the Boards of Protagonist Therapeutics Inc., Arrowhead Pharmaceuticals, and Annexon Inc., serving as Audit Chair. He is also an emeritus Board member of the Association of Bioscience Financial Officers (ABFO) and former Chairman of the Biotechnology Industry Organization (BIO) Business Solutions Advisory Board and Finance and Tax Committee. In his most recent operational role, Mr. Waddill served as Senior Vice President (SVP) and Chief Financial Officer (CFO), of Calithera Biosciences Inc., from 2014 to 2016, which he joined from OncoMed Pharmaceuticals Inc., where he also served as SVP and CFO from 2007 to 2014. Prior to this, Mr. Waddill served as SVP and CFO of Ilypsa Inc., between 2006 and 2007, a biotechnology company that was acquired by Amgen Inc., in 2007. He received a B.S. in Accounting from the University of Illinois, Chicago, and a certification as a public accountant (inactive), after working at PricewaterhouseCoopers LLP and Deloitte LLP in Boston.Reported Earnings • Mar 23Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: US$4.77 loss per share. Revenue: US$19.3m (down 74% from FY 2022). Net loss: US$55.2m (loss widened 78% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Revenue is expected to decline by 94% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 18%.공시 • Feb 22Turnstone Biologics Corp. Announces Demise of P. Joseph Campisi, Jr., Esq, Chief Legal OfficerTurnstone Biologics Corp. announced that P. Joseph Campisi, Jr., Esq, the company’s Chief Legal Officer, passed away on February 1, 2024, following a prolonged battle with cancer.분석 기사 • Jan 23Here's Why We're A Bit Worried About Turnstone Biologics' (NASDAQ:TSBX) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Reported Earnings • Nov 15Third quarter 2023 earnings releasedThird quarter 2023 results: US$0.99 loss per share. Net loss: US$17.3m (flat on 3Q 2022). Revenue is expected to decline by 82% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 15%.공시 • Nov 05Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte Therapy in Solid Tumors At the 2023 Society for Immunotherapy of Cancer Annual MeetingTurnstone Biologics Corp. announced it will be presenting four posters highlighting preclinical data from its pipeline of programs, including the lead clinical candidate, TIDAL-01, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1-5, 2023 in San Diego, California. Key findings from the four poster presentations follow, copies of which will be added to Turnstone’s website and can be accessed here. Title: Expansion and Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes (TIL) from Metastatic Colorectal (CRC) and GI Cancers Date and Time: November 4, 2023, 9:00am - 8:30pm PT Abstract Number: 346 In collaboration with H. Lee Moffitt Cancer Center (Moffitt) Turnstone’s lead Selected TIL clinical candidate, TIDAL-01, utilizes a novel unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of the most potent tumor-reactive (neoantigen-reactive) TIL from the patient’s tumor in vitro, before infusing them into the patient for more targeted tumor killing. This poster demonstrates that TIL from metastatic colorectal cancer and gastric cancer patient samples were successfully expanded from multiple disease sites in vitro. TIL from these samples were screened for neoantigens and enriched for neoantigen-reactive TIL, and furthermore, maintained reactivity following expansion. These results, along with previous findings for TIDAL-01 and from within the field, highlight the practicality of selecting and expanding tumor-reactive TIL as a potential treatment option for colorectal and gastric cancer patients. Title: TBio BFX 4101: A Neoantigen Prioritization Pipeline for Selected Tumor-Infiltrating Lymphocyte Therapy Date and Time: Saturday, November 4, 2023, 9:00am - 8:30pm PT Abstract Number: 900 Identifying tumor-specific neoantigens arising from somatic mutations is one of the differentiating features of Turnstone’s Selected TIL process for TIDAL-01. In this poster, Turnstone presents TBio BFX 4101, a bioinformatics pipeline, which provides a comprehensive and efficient approach to identifying and ranking these neoantigens, with encouraging results from a variety of solid tumor samples, including melanoma, colon, and breast cancers. Title: Tumor Neoantigen Prioritization from Liquid Biopsy Whole Exome Sequencing for Selected Tumor-Infiltrating Lymphocyte Therapy Date and Time: Saturday, November 4, 2023, 9:00am - 8:30pm PT Abstract Number: 178 In collaboration with Illumina Inc. Whole exome DNA and RNA sequencing were applied to patient liquid biopsy samples to assess the sensitivity of tumor variant detection and prioritization of neoantigen peptides in comparison with tissue data. This presentation highlights that minimally invasive liquid biopsy is viable for the detection of somatic variants in preclinical studies, and this approach to identifying neoantigens may increase the breadth and number of tumor-reactive T cells. Title: Enhancing Directly Selected Tumor-Reactive TIL Function Through Genetic Modification Date and Time: Saturday, November 4, 2023, 9:00am - 8:30pm PT Abstract Number: 350 Distinct from, yet complementary to TIDAL-01, Turnstone is developing a preclinical program associated with a next-generation direct selection process. Direct selection utilizes a proprietary combination of markers designed to rapidly select for the greatest breadth of tumor-reactive T cells without the requirement for sequencing or peptide generation. Turnstone scientists are presenting preclinical data highlighting that directly selected tumor-reactive TIL can be genetically engineered using CRISPR-Cas and demonstrate that knocking out genes of interest can potentially enhance directly selected TIL quality and function.Reported Earnings • Sep 04Second quarter 2023 earnings releasedSecond quarter 2023 results: US$7.56 loss per share. Net loss: US$21.5m (flat on 2Q 2022). Revenue is expected to decline by 82% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 15%.Board Change • Jul 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Kanya Rajangam was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.주주 수익률TSBXUS BiotechsUS 시장7D0.06%-3.0%-0.3%1Y-84.2%32.9%26.7%전체 주주 수익률 보기수익률 대 산업: TSBX은 지난 1년 동안 32.9%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: TSBX은 지난 1년 동안 26.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.주가 변동성Is TSBX's price volatile compared to industry and market?TSBX volatilityTSBX Average Weekly Movement7.2%Biotechs Industry Average Movement10.9%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%안정적인 주가: TSBX는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: TSBX의 주간 변동성은 지난 1년간 13%에서 7%로 감소했습니다.회사 소개설립직원 수CEO웹사이트20148Sammy Farahturnstonebio.com턴스톤 바이오로직스는 생명공학 회사로 운영되고 있습니다. 이 회사는 2014년에 설립되었으며 캘리포니아주 샌디에이고에 본사를 두고 있습니다.더 보기Turnstone Biologics Corp. 기초 지표 요약Turnstone Biologics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?TSBX 기초 통계시가총액US$8.21m순이익 (TTM)-US$47.20m매출 (TTM)n/a0.0x주가매출비율(P/S)-0.2x주가수익비율(P/E)TSBX는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표TSBX 손익계산서 (TTM)매출US$0매출원가US$55.63m총이익-US$55.63m기타 비용-US$8.43m순이익-US$47.20m최근 보고된 실적Jun 30, 2025다음 실적 발표일해당 없음주당순이익(EPS)-2.04총이익률0.00%순이익률0.00%부채/자본 비율0%TSBX의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/08/12 15:47종가2025/08/08 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Turnstone Biologics Corp.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Geoffrey MeachamBofA Global ResearchChen YangBofA Global ResearchDaina GrayboschLeerink Partners LLC
공시 • Aug 12Turnstone Biologics Corp.(NasdaqCM:TSBX) dropped from NASDAQ Composite IndexTurnstone Biologics Corp has been dropped from the NASDAQ Composite Index.
공시 • Aug 11XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Turnstone Biologics Corp. (NasdaqCM:TSBX).XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. (NasdaqCM:TSBX) on June 27, 2025. Turnstone will be required to pay XOMA a termination fee of $350,000. If XOMA terminates the Merger Agreement due to the failure of the Closing Net Cash Condition, the Company will be required to pay to XOMA an expense reimbursement fee up to a maximum amount of $350,000. Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the transaction. The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions. Pursuant and subject to the terms of the MergerAgreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remainingshares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Leerink Partners is acting as financial advisor and Divakar Gupta and Rama Padmanabhan of Cooley LLP is acting as legal counsel to Turnstone. Ryan A. Murr and Branden C. Berns of Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty. XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Turnstone Biologics Corp. (NasdaqCM:TSBX) on August 11, 2025. As of the Expiration Date, a total of 17,192,002 shares of Turnstone common stock were validly tendered, and not validly withdrawn, representing approximately 74% of the outstanding shares of Turnstone common stock as of the Expiration Date.
공시 • Jun 27XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp.XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. (NasdaqCM:TSBX) on June 27, 2025. Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the transaction. The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions. Pursuant and subject to the terms of the MergerAgreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remainingshares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Leerink Partners is acting as financial advisor and Cooley LLP is acting as legal counsel to Turnstone. Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty.
공시 • Apr 02Nasdaq Approves to Transfer Listing of Turnstone Biologics Common Stock from Nasdaq Global to Nasdaq Capital MarketAs previously reported, on September 27, 2024, Turnstone Biologics Corp. received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer met the minimum bid price requirement set in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) because the closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company had a 180-calendar day grace period, or until March 26, 2025, to regain compliance with the Minimum Bid Price Requirement. On March 24, 2025, the Company applied to transfer the listing of its common stock from The Nasdaq Global Market to The Nasdaq Capital Market. On March 27, 2025, the Company received approval from the Listing Qualifications Department of Nasdaq to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). The Company’s securities will be transferred to the Capital Market at the opening of business on March 31, 2025. The Company’s common stock will continue to trade under the symbol “TSBX.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. In connection with the Approval, the Company has been granted an additional 180-day grace period, or until September 22, 2025, to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day grace period. If the Company does not regain compliance during this additional grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that in order to regain compliance with the Minimum Bid Price Requirement during the additional grace period, it will implement a reverse stock split, and has filed a proxy statement soliciting a stockholder vote on such reverse stock split. If the Company’s stock becomes subject to delisting as a result of the Company’s failure to regain compliance with the Minimum Bid Price Requirement by September 22, 2025, the Company may appeal the decision to a Nasdaq Hearings Panel. In the event of an appeal, the Company’s common stock would remain listed on the Nasdaq Capital Market pending a written decision by the Nasdaq Hearings Panel following a hearing. In the event that the Nasdaq Hearings Panel determines not to continue the Company’s listing and the Company’s common stock is delisted from The Nasdaq Capital Market, the Company’s common stock may trade on the OTC Bulletin Board or other small trading markets, such as the pink sheets.
Price Target Changed • Apr 01Price target decreased by 58% to US$1.00Down from US$2.38, the current price target is provided by 1 analyst. New target price is 166% above last closing price of US$0.38. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$16.10 next year compared to a net loss per share of US$3.07 last year.
Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Will Waddill was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Aug 12Turnstone Biologics Corp.(NasdaqCM:TSBX) dropped from NASDAQ Composite IndexTurnstone Biologics Corp has been dropped from the NASDAQ Composite Index.
공시 • Aug 11XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Turnstone Biologics Corp. (NasdaqCM:TSBX).XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. (NasdaqCM:TSBX) on June 27, 2025. Turnstone will be required to pay XOMA a termination fee of $350,000. If XOMA terminates the Merger Agreement due to the failure of the Closing Net Cash Condition, the Company will be required to pay to XOMA an expense reimbursement fee up to a maximum amount of $350,000. Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the transaction. The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions. Pursuant and subject to the terms of the MergerAgreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remainingshares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Leerink Partners is acting as financial advisor and Divakar Gupta and Rama Padmanabhan of Cooley LLP is acting as legal counsel to Turnstone. Ryan A. Murr and Branden C. Berns of Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty. XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Turnstone Biologics Corp. (NasdaqCM:TSBX) on August 11, 2025. As of the Expiration Date, a total of 17,192,002 shares of Turnstone common stock were validly tendered, and not validly withdrawn, representing approximately 74% of the outstanding shares of Turnstone common stock as of the Expiration Date.
공시 • Jun 27XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp.XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. (NasdaqCM:TSBX) on June 27, 2025. Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the transaction. The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions. Pursuant and subject to the terms of the MergerAgreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remainingshares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Leerink Partners is acting as financial advisor and Cooley LLP is acting as legal counsel to Turnstone. Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty.
공시 • Apr 02Nasdaq Approves to Transfer Listing of Turnstone Biologics Common Stock from Nasdaq Global to Nasdaq Capital MarketAs previously reported, on September 27, 2024, Turnstone Biologics Corp. received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer met the minimum bid price requirement set in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) because the closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company had a 180-calendar day grace period, or until March 26, 2025, to regain compliance with the Minimum Bid Price Requirement. On March 24, 2025, the Company applied to transfer the listing of its common stock from The Nasdaq Global Market to The Nasdaq Capital Market. On March 27, 2025, the Company received approval from the Listing Qualifications Department of Nasdaq to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). The Company’s securities will be transferred to the Capital Market at the opening of business on March 31, 2025. The Company’s common stock will continue to trade under the symbol “TSBX.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. In connection with the Approval, the Company has been granted an additional 180-day grace period, or until September 22, 2025, to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day grace period. If the Company does not regain compliance during this additional grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that in order to regain compliance with the Minimum Bid Price Requirement during the additional grace period, it will implement a reverse stock split, and has filed a proxy statement soliciting a stockholder vote on such reverse stock split. If the Company’s stock becomes subject to delisting as a result of the Company’s failure to regain compliance with the Minimum Bid Price Requirement by September 22, 2025, the Company may appeal the decision to a Nasdaq Hearings Panel. In the event of an appeal, the Company’s common stock would remain listed on the Nasdaq Capital Market pending a written decision by the Nasdaq Hearings Panel following a hearing. In the event that the Nasdaq Hearings Panel determines not to continue the Company’s listing and the Company’s common stock is delisted from The Nasdaq Capital Market, the Company’s common stock may trade on the OTC Bulletin Board or other small trading markets, such as the pink sheets.
Price Target Changed • Apr 01Price target decreased by 58% to US$1.00Down from US$2.38, the current price target is provided by 1 analyst. New target price is 166% above last closing price of US$0.38. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$16.10 next year compared to a net loss per share of US$3.07 last year.
Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Will Waddill was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 05Turnstone Biologics Corp. Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer Annual MeetingTurnstone Biologics Corp. announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. In collaboration with the University of Montreal Hospital Research Centre (CRCHUM). Although tumor-reactive TIL infused to patients are associated with clinical responses, there are currently no biomarkers that can predict whether tumor-reactive T cells can be expanded from a tumor. Using single T cell sequencing, this poster illustrates a manufacturing method tested to enrich TIL in tumor-reactive T cells, the results for which suggest that the degree of baseline TCR (T cell repertoire) overlap between blood and tumor repertoire could help identify patients from which tumor-reactive TIL can be expanded.
공시 • Oct 11+ 1 more updateTurnstone Biologics Corp. Announces CFO ChangesTurnstone Biologics Corp. announced a strategic prioritization of its pipeline, as well as a workforce reduction of approximately 60% and changes to its leadership team, to focus resources on the continued advancement of its Phase 1 program, TIDAL-01. As a result of the restructuring initiatives that align with the Company’s near-term goals, the anticipated cost savings are expected to extend its cash runway into the second quarter of 2026 and maximize shareholder value. Wendy Worcester, CPA, current Vice President of Finance, will assume responsibility of the Finance function as the Principal Financial and Accounting Officer. Ms. Worcester joined Turnstone in 2022 and is a skilled business and finance professional with over 20 years of financial and accounting experience. Venkat Ramanan, Ph.D., will be stepping down from his role as Chief Financial Officer.
공시 • Oct 02Turnstone Biologics Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market under Listing Rule 5450(a)(1)On September 27, 2024, Turnstone Biologics Corp. received notice (the ‘Notice’) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (‘Nasdaq’) that, because the closing bid price of Turnstone’s common stock was below $1.00 per share for 30 consecutive business days, Turnstone no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of Turnstone’s common stock on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until March 26, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to March 26, 2025. If Turnstone does not regain compliance by March 26, 2025, the Company may be eligible for an additional 180 calendar day grace period if it applies to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. To qualify, Turnstone would be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards, with the exception of the minimum bid price requirement, and provide written notice to Nasdaq of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff determines that Turnstone will not be able to cure the deficiency, or if Turnstone is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that Turnstone’s common stock will be subject to delisting. Turnstone is presently evaluating potential actions to regain compliance with the continued listing requirements of Nasdaq. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.
공시 • Aug 15Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal CancerTurnstone Biologics Corp. reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer (“MSS mCRC”). Turnstone’s Phase 1 STARLING trial is an ongoing muti-site, first-in-human, non-randomized, open label, single-dose study, and is evaluating the safety, tolerability, and clinical activity of TIDAL-01. The trial is currently enrolling patients with colorectal cancer, head and neck squamous cell carcinoma, and uveal melanoma. As of the cutoff date of July 15, 2024, key takeaways from the initial data include the following: Clinical Responses: Among the four evaluable MSS mCRC patients included in the study, Turnstone observed a 25% overall response rate ("ORR") and 50% disease control rate ("DCR"). One patient demonstrated a deep and durable ongoing complete response (CR). Durability of Response: 50% of patients showed sustained clinical benefit, with notable progression free survival of over one year in the patient with ongoing complete response and 6 months for a patient with stable disease. Translational Profile: The TIDAL-01 process demonstrated the ability to generate high titer, polyclonal and multi-epitope tumor neoantigen-reactive T cells that expanded in the patient, persisted in the blood and correlated with an increase in CD8 T cell tumor infiltration. Tolerability Profile: TIDAL-01 was generally well-tolerated and safety events observed were consistent with known AEs associated with the lymphodepletion regimen, and IL-2 and pembrolizumab administration. Manufacturing Rates: The manufacturing success rate for TIDAL-01 in CRC for patients with sufficient starting material was 80%, which is consistent with other early clinical-stage cell therapy processes. The target dose of at least 1x10 total T cells was exceeded in all manufactured CRC products.
공시 • Jul 03Turnstone Biologics Corp.(NasdaqGM:TSBX) dropped from Russell 3000 IndexTurnstone Biologics Corp.(NasdaqGM:TSBX) dropped from Russell 3000 Index
분석 기사 • May 08We're A Little Worried About Turnstone Biologics' (NASDAQ:TSBX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
공시 • Apr 24Turnstone Biologics Corp., Annual General Meeting, Jun 03, 2024Turnstone Biologics Corp., Annual General Meeting, Jun 03, 2024, at 13:30 Pacific Standard Time. Agenda: To elect the three nominees for Class I directors named in the accompanying proxy statement (the “Proxy Statement”) to hold office until the 2027 Annual Meeting of Stockholders and his or her successor has been duly elected and qualified or, if sooner, until such director’s earlier death, resignation or removal; to ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting.
공시 • Apr 17Turnstone Biologics Corp. Announces Board ChangesTurnstone Biologics Corp. announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. Mr. Waddill brings more than three decades of financial and operational expertise in the biotechnology space, and proven leadership in industry organizations. Mr. Waddill currently sits on the Boards of Protagonist Therapeutics Inc., Arrowhead Pharmaceuticals, and Annexon Inc., serving as Audit Chair. He is also an emeritus Board member of the Association of Bioscience Financial Officers (ABFO) and former Chairman of the Biotechnology Industry Organization (BIO) Business Solutions Advisory Board and Finance and Tax Committee. In his most recent operational role, Mr. Waddill served as Senior Vice President (SVP) and Chief Financial Officer (CFO), of Calithera Biosciences Inc., from 2014 to 2016, which he joined from OncoMed Pharmaceuticals Inc., where he also served as SVP and CFO from 2007 to 2014. Prior to this, Mr. Waddill served as SVP and CFO of Ilypsa Inc., between 2006 and 2007, a biotechnology company that was acquired by Amgen Inc., in 2007. He received a B.S. in Accounting from the University of Illinois, Chicago, and a certification as a public accountant (inactive), after working at PricewaterhouseCoopers LLP and Deloitte LLP in Boston.
Reported Earnings • Mar 23Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: US$4.77 loss per share. Revenue: US$19.3m (down 74% from FY 2022). Net loss: US$55.2m (loss widened 78% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Revenue is expected to decline by 94% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 18%.
공시 • Feb 22Turnstone Biologics Corp. Announces Demise of P. Joseph Campisi, Jr., Esq, Chief Legal OfficerTurnstone Biologics Corp. announced that P. Joseph Campisi, Jr., Esq, the company’s Chief Legal Officer, passed away on February 1, 2024, following a prolonged battle with cancer.
분석 기사 • Jan 23Here's Why We're A Bit Worried About Turnstone Biologics' (NASDAQ:TSBX) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Reported Earnings • Nov 15Third quarter 2023 earnings releasedThird quarter 2023 results: US$0.99 loss per share. Net loss: US$17.3m (flat on 3Q 2022). Revenue is expected to decline by 82% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 15%.
공시 • Nov 05Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte Therapy in Solid Tumors At the 2023 Society for Immunotherapy of Cancer Annual MeetingTurnstone Biologics Corp. announced it will be presenting four posters highlighting preclinical data from its pipeline of programs, including the lead clinical candidate, TIDAL-01, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1-5, 2023 in San Diego, California. Key findings from the four poster presentations follow, copies of which will be added to Turnstone’s website and can be accessed here. Title: Expansion and Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes (TIL) from Metastatic Colorectal (CRC) and GI Cancers Date and Time: November 4, 2023, 9:00am - 8:30pm PT Abstract Number: 346 In collaboration with H. Lee Moffitt Cancer Center (Moffitt) Turnstone’s lead Selected TIL clinical candidate, TIDAL-01, utilizes a novel unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of the most potent tumor-reactive (neoantigen-reactive) TIL from the patient’s tumor in vitro, before infusing them into the patient for more targeted tumor killing. This poster demonstrates that TIL from metastatic colorectal cancer and gastric cancer patient samples were successfully expanded from multiple disease sites in vitro. TIL from these samples were screened for neoantigens and enriched for neoantigen-reactive TIL, and furthermore, maintained reactivity following expansion. These results, along with previous findings for TIDAL-01 and from within the field, highlight the practicality of selecting and expanding tumor-reactive TIL as a potential treatment option for colorectal and gastric cancer patients. Title: TBio BFX 4101: A Neoantigen Prioritization Pipeline for Selected Tumor-Infiltrating Lymphocyte Therapy Date and Time: Saturday, November 4, 2023, 9:00am - 8:30pm PT Abstract Number: 900 Identifying tumor-specific neoantigens arising from somatic mutations is one of the differentiating features of Turnstone’s Selected TIL process for TIDAL-01. In this poster, Turnstone presents TBio BFX 4101, a bioinformatics pipeline, which provides a comprehensive and efficient approach to identifying and ranking these neoantigens, with encouraging results from a variety of solid tumor samples, including melanoma, colon, and breast cancers. Title: Tumor Neoantigen Prioritization from Liquid Biopsy Whole Exome Sequencing for Selected Tumor-Infiltrating Lymphocyte Therapy Date and Time: Saturday, November 4, 2023, 9:00am - 8:30pm PT Abstract Number: 178 In collaboration with Illumina Inc. Whole exome DNA and RNA sequencing were applied to patient liquid biopsy samples to assess the sensitivity of tumor variant detection and prioritization of neoantigen peptides in comparison with tissue data. This presentation highlights that minimally invasive liquid biopsy is viable for the detection of somatic variants in preclinical studies, and this approach to identifying neoantigens may increase the breadth and number of tumor-reactive T cells. Title: Enhancing Directly Selected Tumor-Reactive TIL Function Through Genetic Modification Date and Time: Saturday, November 4, 2023, 9:00am - 8:30pm PT Abstract Number: 350 Distinct from, yet complementary to TIDAL-01, Turnstone is developing a preclinical program associated with a next-generation direct selection process. Direct selection utilizes a proprietary combination of markers designed to rapidly select for the greatest breadth of tumor-reactive T cells without the requirement for sequencing or peptide generation. Turnstone scientists are presenting preclinical data highlighting that directly selected tumor-reactive TIL can be genetically engineered using CRISPR-Cas and demonstrate that knocking out genes of interest can potentially enhance directly selected TIL quality and function.
Reported Earnings • Sep 04Second quarter 2023 earnings releasedSecond quarter 2023 results: US$7.56 loss per share. Net loss: US$21.5m (flat on 2Q 2022). Revenue is expected to decline by 82% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 15%.
Board Change • Jul 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Kanya Rajangam was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
